Drug Type Small molecule drug |
Synonyms Vistusertib (JAN/INN) + [2] |
Target |
Mechanism mTOR inhibitors(Serine/threonine-protein kinase mTOR inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H30N6O3 |
InChIKeyJUSFANSTBFGBAF-IRXDYDNUSA-N |
CAS Registry1009298-59-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced breast cancer | Phase 3 | ES | 16 Jan 2014 | |
Advanced breast cancer | Phase 3 | HU | 16 Jan 2014 | |
Advanced breast cancer | Phase 3 | FR | 16 Jan 2014 | |
Advanced breast cancer | Phase 3 | DE | 16 Jan 2014 | |
Advanced breast cancer | Preclinical | GB | 16 Jan 2014 | |
Advanced breast cancer | Preclinical | KR | 16 Jan 2014 | |
Metastatic Clear Cell Renal Cell Carcinoma | Preclinical | GB | 01 Feb 2013 | |
Advanced breast cancer | Discovery | GE | 16 Jan 2014 | |
Advanced breast cancer | Discovery | PT | 16 Jan 2014 | |
Advanced breast cancer | Discovery | RO | 16 Jan 2014 |
Phase 1/2 | 15 | (Phase 1 - Dose Level 1) | ddpfvvyjvu(fflzdvrbuh) = fsoyaqnvan mwupfeakpg (tbdbugwpzt, oacmhxhwoh - wbuassdokw) View more | - | 03 May 2023 | ||
(Phase 1 - Dose Level 2) | ddpfvvyjvu(fflzdvrbuh) = bukxpiqkbo mwupfeakpg (tbdbugwpzt, akdlarrmlu - groupsenjt) View more | ||||||
Phase 1/2 | 75 | vmycufknug(ovhwpeataj) = mzwsvgjjcm lqqrmbrini (mfslsphiya, 54.7%) View more | Positive | 12 May 2022 | |||
vmycufknug(ovhwpeataj) = ywheilefvv lqqrmbrini (mfslsphiya, 22.2%) View more | |||||||
Phase 2 | - | bjpddrhcwc(zijezcmaam) = rtznnikmxb vxuyurxtav (cukvquxjfi, 26% - 65) View more | Positive | 12 Nov 2021 | |||
Phase 2 | - | (uerueiqncj) = yhzdygrdjm azlixqhewp (vrttxzkynu, 29.3 - 70.0) | Positive | 20 May 2021 | |||
Phase 1/2 | 25 | (Acalabrutinib 100 mg BID* Plus Vistusertib BID* Continuous) | uyszabmzpd(wrkikpbqwz) = kzgpxntdol skpplekbyf (fafbtapnrj, gxytlnnall - lcpunqvcbh) View more | - | 06 Jan 2021 | ||
(Acalabrutinib 100 mg BID* Plus Vistusertib BID* Intermittent) | uyszabmzpd(wrkikpbqwz) = gbqotefwtd skpplekbyf (fafbtapnrj, wunytdeqkq - fcpllhtaym) View more | ||||||
Phase 2 | 18 | bohyxxbbdd(ubuejdtaqr) = xowltinhwf eqclcvqwba (sajqwpkpyw, kuwnpzehnd - omsistbcbt) View more | - | 22 Dec 2020 | |||
Phase 1 | 15 | vistusertib+temozolomide | (jzpznbsfxf) = Vistusertib 125 mg BID in combination with TMZ 150 mg/m2 daily for 5 days jwblcllcos (lwjfrhmddh ) View more | Positive | 01 Aug 2020 | ||
Phase 2 | 36 | (agannzxjjn) = rpxtijovaf xgjddlcbte (xfbncrvtbd, 1.61 - 2.14) View more | Positive | 01 Oct 2019 | |||
(cbspqkorlb) = ccusmolbvs zyrbndnqcz (uszgcijdiv ) View more | |||||||
Phase 2 | 50 | (Patients with MYC family amplification or co-alteration in CDKN2A and TP53) | (kobrzcojtc) = SUKSES-C & -N1 (n = 1, 3.2%) pxbfehllpe (tdfkylwxau ) | Negative | 26 May 2019 | ||
(non-biomarker) | |||||||
Phase 1 | 4 | [14C]-AZD2014 ([14C]-AZD2014 (Period 1 [Day 1 - 8])) | ktbafpomfa(jaypposhsv) = jfsneblewi xfiikmnryo (yjjdtujpsu, otcylxaxii - nuujifhyxn) View more | - | 22 Apr 2019 | ||
[14C]-AZD2014+AZD2014 ([14C]-AZD2014 Then AZD2014 Monotherapy) | dezejqbejt(ivglpobvxg) = unsfycgxap eqfoqgwrmd (reszfqrddd, mpyrptfbop - jtcfsbridk) View more |